Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.48 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861787 | 0.88 | TRPV1 (0.51) | TRPV1MAPK3 | |
| SCHEMBL1864901 | 0.86 | TRPV1 (0.42) | TRPV1ACP1RAB9A | |
| SCHEMBL13622817 | 0.85 | TRPV1 (0.68) | TRPV1MAPK3 | |
| SCHEMBL1862095 | 0.84 | TRPV1 (0.48) | TRPV1ACP1MAPK3RAB9A | |
| SCHEMBL1862403 | 0.83 | TRPV1 (0.54) | TRPV1ACP1 | |
| SCHEMBL13622816 | 0.80 | TRPV1 (0.60) | TRPV1MAPK3 | |
| SCHEMBL4475695 | 0.80 | TRPV1 (0.55) | TRPV1MAPK3 | |
| SCHEMBL4359111 | 0.79 | TRPV1 (0.54) | TRPV1MAPK3 | |
| SCHEMBL4354994 | 0.78 | TRPV1 (0.57) | TRPV1MAPK3 | |
| SCHEMBL4476847 | 0.78 | TRPV1 (0.65) | TRPV1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | TRPV1 549/4885ACP1 2981/4885MAPK3 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.